What's breaking now, across thousands of outlets.
The acquisition is set to give Integris access to extra capital and technology at a time when many health systems are being hit by rising expenses.
We haven't written up this one. Healthcare Dive has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
U.S. regulators have accepted a new submission for Vyglxia, offering the chance at a turnaround for another rare disease medicine spurned by previous FDA leadership.
A needle-free vaccination method protected mice against the viruses that cause COVID-19 and flu, offering a possible new way to deliver mRNA vaccines while limiting unwanted inflammation.
It’s the latest insurer to report momentum in the safety-net insurance program as states increase their payment rates and costs plateau.
(MedPage Today) -- No patient today should face the risk of acquiring HIV. That means we need to focus our attention on people who could benefit from HIV preexposure prophylaxis (PrEP) but are not…
Roche is gearing up for a major launch in the shape of its breast cancer pill giredestrant, and according to Teresa Graham, head of the company’s pharma unit, patients are clamoring to get hold of ...
Hospital Superintendent says decision to provide SMA patients with a less expensive, generic version of the original molecule against SMA, in place of the imported original drug costing several lakhs…
